{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:19:28Z","timestamp":1787026768512,"version":"build-2736575974"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>To explore the combined diagnostic value of plasma Lewy body-associated proteins (p-Asyn at ser129, total \u03b1-syn, and oligomeric \u03b1-syn) for the diagnosis of PD versus healthy controls (HCs) and other PD syndromes (PDs), as well as clinical characteristics prediction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included 145 participants: 79 patients with PD, 24 patients with PDs, and 42 HCs. A panel of plasma levels of p-Asyn, total \u03b1-syn, and oligomeric \u03b1-syn was measured by enzyme-linked immunosorbent assay (ELISA). The primary outcome was the discriminative accuracy of the combined three plasma biomarkers for PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean age was 65.43 (SD, 7.467) in the control group, 64.49 (SD, 8.224) in participants with PD, and 69.25 (SD, 7.952) in PDs. The plasma Lewy body-associated protein levels were significantly higher in patients with PD than in age-matched HCs, However, there was no difference in patients with PD and PDs. Of note, a combination of plasma p-Asyn, total \u03b1-syn, and oligomeric \u03b1-syn was a better biomarker for discriminating PD from HCs, with an AUC of 0.8552 (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.0001, 95%CI, 0.7635\u20130.9409), which was significantly higher than plasma p-Asyn (\u0394AUC, 0.1797), total \u03b1-syn (\u0394AUC, 0.0891) and oligomeric \u03b1-syn (\u0394AUC, 0.1592) alone. Meanwhile, Lewy body-associated proteins had no connections between different motor stages and dementia performances.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results suggested that plasma Lewy body-associated proteins, may serve as a non-invasive biomarker to aid the diagnosis of PD from HCs. In addition, increased plasma Lewy body-associated proteins were not associated with the progression of motor and non-motor symptoms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2022.869797","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T04:03:08Z","timestamp":1652328188000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Lewy Body-Associated Proteins A-Synuclein (a-syn) as a Plasma-Based Biomarker for Parkinson\u2019s Disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Xuemiao","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuoting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangjie","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ane.12590","article-title":"Cerebrospinal fluid biomarkers for Parkinson\u2019s disease - a systematic review.","volume":"135","author":"Andersen","year":"2017","journal-title":"Acta Neurol. Scand."},{"key":"B2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bpa.12370","article-title":"Alpha-Synuclein as a biomarker for Parkinson\u2019s disease.","volume":"26","author":"Atik","year":"2016","journal-title":"Brain Pathol."},{"key":"B3","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1212\/WNL.0b013e3181fd6393","article-title":"CSF alpha-synuclein as a diagnostic biomarker for Parkinson disease and related dementias.","volume":"75","author":"Ballard","year":"2010","journal-title":"Neurology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.neuron.2013.09.004","article-title":"The function of alpha-synuclein.","volume":"79","author":"Bendor","year":"2013","journal-title":"Neuron"},{"key":"B5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1212\/WNL.0b013e31827b90d1","article-title":"Naturally occurring alpha-synuclein autoantibody levels are lower in patients with Parkinson disease.","volume":"80","author":"Besong-Agbo","year":"2013","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson\u2019s disease.","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01388","article-title":"Plasma and serum Alpha-synuclein as a biomarker of diagnosis in patients with Parkinson\u2019s disease.","volume":"10","author":"Chang","year":"2019","journal-title":"Front. Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1096\/fj.03-1449com","article-title":"Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson\u2019s disease.","volume":"20","author":"El-Agnaf","year":"2006","journal-title":"FASEB J."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/srep02540","article-title":"A longitudinal study on alpha-synuclein in blood plasma as a biomarker for Parkinson\u2019s disease.","volume":"3","author":"Foulds","year":"2013","journal-title":"Sci. Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1096\/fj.10-179192","article-title":"Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson\u2019s disease.","volume":"25","author":"Foulds","year":"2011","journal-title":"FASEB J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/jnnp-2016-314857","article-title":"Plasma alpha-synuclein predicts cognitive decline in Parkinson\u2019s disease.","volume":"88","author":"Lin","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/ene.14208","article-title":"A longitudinal study on alpha-synuclein in plasma neuronal exosomes as a biomarker for Parkinson\u2019s disease development and progression.","volume":"27","author":"Niu","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders.","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease.","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"B15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1515\/revneuro-2012-0071","article-title":"The role of Ser129 phosphorylation of alpha-synuclein in neurodegeneration of Parkinson\u2019s disease: a review of in vivo models.","volume":"24","author":"Sato","year":"2013","journal-title":"Rev. Neurosci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1074\/mcp.R113.032730","article-title":"Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies.","volume":"12","author":"Schmid","year":"2013","journal-title":"Mol. Cell. Proteomics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3233\/JAD-181152","article-title":"Cerebrospinal fluid and plasma biomarkers in Neurodegenerative diseases.","volume":"68","author":"Seino","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.1090278","article-title":"alpha-Synuclein locus triplication causes Parkinson\u2019s disease.","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009399","article-title":"alpha-Synuclein in Parkinson\u2019s disease.","volume":"2","author":"Stefanis","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/bs.ircmb.2015.07.007","article-title":"Intracellular dynamics of synucleins: \u201cHere, There and Everywhere\u201d.","volume":"320","author":"Surguchov","year":"2015","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-019-0155-y","article-title":"Erythrocytic alpha-Synuclein as a potential biomarker for Parkinson\u2019s disease.","volume":"8","author":"Tian","year":"2019","journal-title":"Transl. Neurodegener."},{"key":"B22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/ana.25447","article-title":"alpha-Synuclein real-time quaking-induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism.","volume":"85","author":"van Rumund","year":"2019","journal-title":"Ann. Neurol."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00595","article-title":"Biofluid markers for prodromal parkinson\u2019s disease: evidence from a catecholaminergic perspective.","volume":"11","author":"Vermeiren","year":"2020","journal-title":"Front. Neurol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14175-5","article-title":"Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson\u2019s disease.","volume":"7","author":"Vicente Miranda","year":"2017","journal-title":"Sci. Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ejn.13056","article-title":"Oligomeric alpha-synuclein and beta-amyloid variants as potential biomarkers for Parkinson\u2019s and Alzheimer\u2019s diseases.","volume":"43","author":"Williams","year":"2016","journal-title":"Eur. J. Neurosci."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2022.869797\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T04:03:11Z","timestamp":1652328191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2022.869797\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":25,"alternative-id":["10.3389\/fnagi.2022.869797"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2022.869797","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]},"article-number":"869797"}}